Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Gain Therapeutics doses two subjects in Parkinson's therapy trial

Is Gain Therapeutics Inc (GANX) a Good Buy in the Biotechnology

Success story interview with Dr. Manolo Bellotto, Gain

Minoryx Therapeutics spins off SEE-Tx platform into new company

Gain Therapeutics cleared to start study of GT-02287 in Australia

The Future Is Now: Matthias Alder Of Gain Therapeutics On How

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial

Gain Therapeutics (@GainThera) / X

Behind the scenes of Gain Therapeutics COO: Matthias Alder

Gain The Edge Official Reviews Read Customer Service Reviews of gaintheedgeofficial.com

Gain Flings Original HE Laundry Detergent (72-Count) in the Laundry Detergent department at

The 48 Best Lifegain Cards in Magic Ranked - Draftsim

The Snake Statue, Harvest Town Wiki

Cleric Class (Adventures in the Forgotten Realms) - Gatherer